By Connor Hart
Hims & Hers Health raised its full-year outlook after it swung to a profit in the third quarter boosted by a tax benefit and consumer demand for weight-loss drugs.
The telehealth-consultation platform on Monday reported net income of $76 million, or 32 cents a share, compared with a loss of $7.4 million, or 4 cents a share, in the same quarter last year.
The recent quarter's profit included a $60.8 million tax benefit related to the release of a tax valuation allowance, which was partially offset by current period tax expense, the company said.
Revenue surged 77% to $401.6 million. Analysts polled by FactSet were expecting $382.2 million.
The San Francisco-based company now has more than 2 million subscribers, up from about 1.4 million at the end of the year-ago quarter. Average monthly online revenue per subscriber rose to $67 from $54.
Chief Financial Officer Yemi Okupe said subscriber growth, excluding contributions from the company's weight-loss solutions, increased 40% from last year on improved brand awareness and broader personalization initiatives.
"Our new weight loss offering is helping a growing number of people and providing an accelerant to what was already a robust trajectory," he said.
For the fourth quarter, Hims & Hers forecast revenue between $465 million and $470 million, ahead of the $421.1 million that analysts are looking for, according to FactSet.
For the year, the company expects revenue between $1.46 billion and $1.47 billion, up from its prior projection for between $1.37 billion and $1.4 billion. Analysts surveyed by FactSet are expecting $1.4 billion.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
November 04, 2024 16:27 ET (21:27 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.